Cumulative metformin linked to mortality post-prostate cancer

August 8, 2013
Cumulative metformin linked to mortality post-prostate cancer
Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer diagnosis correlates with decreased all-cause and prostate cancer-specific mortality, according to a study published online Aug. 5 in the Journal of Clinical Oncology.

(HealthDay)—Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer (PC) diagnosis correlates with decreased all-cause and PC-specific mortality, according to a study published online Aug. 5 in the Journal of Clinical Oncology.

David Margel, M.D., Ph.D., from the University of Toronto, and colleagues analyzed data from several Ontario health care administrative databases to identify men (>66 years) with incident diabetes who subsequently developed PC. Within the cohort of 3,837 patients, they examined the impact of duration of antidiabetic medication exposure following diagnosis with PC on all-cause and PC-specific mortality.

The researchers found that the median age at PC diagnosis was 75 years. Over a median of 4.64 years of follow-up, 35 percent of patients died, with 7.6 percent dying from PC. The risk of PC-specific and all-cause mortality was significant decreased, in a dose-dependent manner, for cumulative duration of treatment after PC diagnosis. For PC-specific mortality, the adjusted hazard ratio was 0.76 for each additional six months of metformin use. There was also a significant association with all-cause mortality but it declined over time, from a hazard ratio of 0.76 in the first six months to 0.93 between 24 and 30 months. For other antidiabetic drugs there was no relationship with cumulative use and either outcome.

"Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and PC-specific mortality among diabetic men," the authors write.

Explore further: Lung cancer risk unaffected by metformin use in diabetes

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Statin use at cancer diagnosis linked to lower mortality

November 8, 2012

(HealthDay)—For patients with cancer, statin use prior to diagnosis correlates with reduced all-cause and cancer-related mortality, according to a study published in the Nov. 8 issue of the New England Journal of Medicine.

Rate of nephrectomy at lymph node dissection is declining

April 3, 2013

(HealthDay)—Over the last 30 years, the incidence of nephrectomy at post-chemotherapy (PC) retroperitoneal lymph node dissection (RPLND) has steadily declined, according to research published in the March issue of The Journal ...

Post-breast cancer, metformin has no effect on mortality

July 3, 2013

(HealthDay)—For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.